Stifel says Q3 organic revenue growth ex-currency and ex-M&A at Boston Scientific (BSX) was “an outstanding 18.2%,” making this quarter’s organic growth the fastest since 2003/2004, excluding the 2021 Covid recovery growth. However, the stock is trading lower today, which the firm suspects is due to the company’s comments about the AVANTGUARD Farapulse trial enrollment pause and some element of “sell the (positive) news.” The firm, which says it is “inclined to view today’s stock-performance as a buying-opportunity,” and thinks Boston Scientific is “positioned for another excellent growth year in 2025,” maintains a Buy rating and $100 price target on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BSX:
- Boston Scientific price target raised to $97 from $93 at BTIG
- Unusually active option classes on open October 23rd
- Boston Scientific raises FY24 adjusted EPS view to $2.45-$2.47 from $2.38-$2.42
- Boston Scientific reports Q3 adjusted EPS 63c, consensus 59c
- Boston Scientific sees Q4 adjusted EPS 64c-66c, consensus 64c
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
